Vincerx Pharma, Inc. (VINC)
| Market Cap | 19.67M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -56.01M |
| Shares Out | 21.38M |
| EPS (ttm) | -2.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,480 |
| Open | 0.925 |
| Previous Close | 0.909 |
| Day's Range | 0.875 - 0.925 |
| 52-Week Range | 0.631 - 1.950 |
| Beta | 0.26 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+334.78%) |
| Earnings Date | Nov 9, 2023 |
About VINC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic m... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for VINC stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 334.78% from the latest price.
News
Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023
PALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through parad...
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943
Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL
Vincerx Pharma Announces FDA Clearance of IND for VIP943
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx' first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx's development a...
Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
IND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023 Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class SMDC Cash bala...
Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class α v β 3 small molecule drug conjugate (SMDC) for the treatment of solid tumors
Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting
VIP924, a first-in-class CXCR5-ADC showed significant activity in patient-derived (PDX) lymphoma mouse models VIP924, a first-in-class CXCR5-ADC showed significant activity in patient-derived (PDX) ly...
Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023
Latest small molecule drug conjugates (SMDCs) strengthen company strategy to discover and develop paradigm-shifting drug conjugates Latest small molecule drug conjugates (SMDCs) strengthen company str...
Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting
VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived (PDX) mouse models and metastatic PDX mouse models across several tumor types VIP...
Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an α v β 3 small molecule drug conjugate (SMDC) in advanced solid tumors
Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023
PALO ALTO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through parad...
Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference
PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradi...
Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236
VIP236 is a first-in-class α V β 3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications
Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types
In a multiple myeloma (MM) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-MM agents
Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022
Vincerx's proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) ...
Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Received Orphan Drug Designation for enitociclib; continue to focus on priority indications
Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022
PALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradi...
Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Continue to execute on priority indications for VIP152; recently issued the INN enitociclib
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation
Analysts Cuts Price Target On This Small Cap But Remain Bullish
Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on i...
Vincerx Pharma Provides Key Strategic Update
Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL
Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting
Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies
Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101
Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through parad...
Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradi...